Gene therapy developer Limelight Bio grew from research at University of Pennsylvania and has landed $75m in its first publicly-disclosed round.
Limelight Bio, a US-based gene editing platform and therapy developer founded on University of Pennsylvania (UPenn) research, secured $75m yesterday in a round led by life sciences-focused VC firm Apple Tree Partners.
Founded in 2017, Limelight Bio is developing gene-based therapeutics for indications unaddressed by existing drugs, including severe genetic disorders affecting the ear, retina, blood and metabolism.
The company has already identified multiple drug candidates using its gene-editing technology, which it claims can remedy larger genetic defects…
